FiercePharma

FTC Study: In FY 2012, Branded Drug Firms Significantly Increased the Use of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the Market

Record Number of Agreements Cover 31 Different Products, With Combined Annual U.S. Sales of More Than $8.3 Billion In Fiscal Year (FY) 2012, the number of potentially anticompetitive patent dispute ...
USA Today

Ten brands that lost the most value

Research in Motion, Blackberry maker, biggest 2012 loser in brand value rankings Apple, expected to eclipse longstanding leader Coca-Cola, by 2013 Automakers, financial services companies struggling ...
searchenginewatch

Branded vs. Non-Branded SEM

Whether a company should bid on their own brand name to fortify their search position is a subject of fierce debate. There are reasonable arguments both for and against the issue. This article is ...
IPWatchdog

In FY 2012, Branded Drug Firms Increased the Use of Pay-for-Delay Settlements to Keep Generic Competitors off the Market

In Fiscal Year (FY) 2012, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased significantly compared with FY 2011, jumping from 28 ...